Managed Care News and Research

RSS

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease.

2 Sep 2015

Partners Urgent Care announces opening of first urgent care center in Brookline, Massachusetts

Partners Urgent Care today announced the opening of its first urgent care center in the town of Brookline, Massachusetts at 1285 Beacon Street. Partners Urgent Care is a collaboration between Partners HealthCare, an integrated health care system founded by Massachusetts General Hospital and Brigham and Women's Hospital, and MedSpring Urgent Care.

1 Sep 2015

AMCP issues statement in response to FDA’s draft guidance requiring nonproprietary names for biological products

The Academy of Managed Care Pharmacy (AMCP) is disappointed in the Food and Drug Administration's (FDA's) draft guidance and proposed rule that calls for biologics, including reference products and biosimilars, to bear a nonproprietary name with an FDA-designated suffix.

28 Aug 2015

Variations in opioid receptor genes linked to neonatal abstinence syndrome severity in newborn babies

A new study led by researchers at Boston Medical Center indicates that variations in opioid receptor genes are associated with more severe neonatal abstinence syndrome (NAS) in newborn babies. The findings, published online in Drug & Alcohol Dependence, could help lead to the development of individualized treatment plans tailored to each infants' risk of requiring medication to curb their NAS symptoms, which could help improve these patients' outcomes and reduce how long some stay in the hospital.

26 Aug 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.

26 Aug 2015

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

In response to the growing opioid crisis, several states, including Massachusetts and Rhode Island, have granted pharmacists the authority to provide naloxone rescue kits without a prescription to at-risk patients. This model of pharmacy-based naloxone (PBN) education and distribution is one of the public health strategies currently being evaluated at hundreds of pharmacies in both states to determine the impact on opioid overdose death rates.

25 Aug 2015

Inovalon signs definitive agreement to acquire Avalere Health

Inovalon, a leading technology company providing advanced, cloud-based data analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Avalere Health, Inc., a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.

25 Aug 2015

Education intervention can improve physicians’ understanding of transgender issues

The term "transgender" has made its way into mainstream media thanks to Caitlyn Jenner, previously known as Bruce Jenner, who came out as a transgender woman earlier this year.

11 Aug 2015

BMC partners with RIH, CVS to support pharmacy-based naloxone rescue kits to help combat opioid addiction, overdose

Boston Medical Center has received a $1.3 million grant from the Agency for Healthcare Research and Quality to support a demonstration project of pharmacy-based naloxone rescue kits to help reduce opioid addiction and overdose death in two New England States: Massachusetts and Rhode Island.

7 Aug 2015

New health care program covered by Medicaid improves some aspects of care for disabled adults

UF Health researchers have found that care linked to heart attacks and chronic obstructive pulmonary disease, or COPD, among disabled adults covered by Medicaid has improved with the expansion of a new health care program in Texas over the last decade.

5 Aug 2015

Armada, UMass Medical School partner to enhance ArmadaOne Specialty Pharmacy Workflow Platform

Armada Health Care has partnered with University of Massachusetts Medical School's Clinical Pharmacy Services business unit to provide enhancements and support regarding clinical protocols and therapy interventions within the ArmadaOne Specialty Pharmacy Workflow Platform.

4 Aug 2015

Centene reports strong financial results for Q2 2015

Centene Corporation today announced its financial results for the quarter ended June 30, 2015. The following discussions, with the exception of cash flow information, are in the context of continuing operations.

28 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

TechSource National announces acquisition of IMEBASE product

TechSource National is pleased to announce the asset purchase of IMEBASE, a web-based application designed to create, track and complete independent medical examinations, medical peer reviews and other medical evaluative services.

16 Jul 2015

Centene to acquire Health Net shares for approximately $6.8 billion

Centene Corporation and Health Net, Inc. announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which Centene will acquire all of the shares of Health Net in a cash and stock transaction valued at approximately $6.8 billion, including the assumption of approximately $500 million of debt.

2 Jul 2015

Telesta submits Biologics License Application for MCNA to FDA

Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy.

30 Jun 2015

$Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC$

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.

19 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

U.S. states with stronger alcohol policies have lower rates of youth drinking

A new study by Boston University and Boston Medical Center researchers reveals that U.S. states with stronger alcohol policies have lower rates of youth overall drinking and binge drinking. The study's results, published in the journal Pediatrics, further suggest that the link is largely a result of policies intended mostly for adults and their effects on reducing adult binge drinking.

2 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015